What are the adverse effects and cautions associated with daridorexant based on trial data?

Daridorexant Adverse Effects and Cautions Based on Trial Data

Daridorexant demonstrates a favorable safety profile with somnolence and fatigue as the primary adverse effects, occurring at rates only slightly higher than placebo, while serious adverse events remain rare and comparable to placebo across all approved doses.

Primary Adverse Effects

Most Common Side Effects

The FDA-approved labeling and clinical trials consistently identify the following adverse effects 1, 2:

• Somnolence: Most frequent adverse effect

  • 7% with daridorexant 50 mg vs. 3% with placebo
  • 5.1-8.4% with 15-20 mg doses
  • Typically mild to moderate intensity
  • Rarely leads to discontinuation
  • Risk increases with age - elderly patients at higher risk 1

• Fatigue: Second most common adverse effect

  • Significantly elevated compared to placebo (RR 2.01,95% CI 1.21-3.36) 3
  • Also shows age-related increase in frequency

• Nasopharyngitis and Headache: Commonly reported but comparable to placebo rates 2

Overall Adverse Event Profile

Meta-analysis data shows slightly elevated overall adverse event rates 3:

• Overall adverse events: RR 1.19 (95% CI 1.05-1.35)
• Incidence comparable across treatment groups: 38-39% vs. 33-34% placebo 2
• No significant increase in serious adverse events compared to placebo
• Withdrawal rates due to adverse effects not significantly different from placebo 2

Critical Safety Warnings and Cautions

CNS Depression and Falls Risk

The most clinically significant concern is CNS depression, particularly in vulnerable populations 1:

• Elderly patients: Substantially higher risk of falls due to increased somnolence and drowsiness
• Avoid alcohol: Additive impairment of psychomotor performance
• CNS depressants: Use with caution; consider dose adjustment of daridorexant and/or concomitant CNS depressants

Neuropsychiatric Effects

FDA labeling warns of potential cognitive and behavioral changes 1:

• Complex behaviors (e.g., sleep-driving)
• Amnesia
• Anxiety
• Hallucinations (hypnagogic/hypnopompic)
• Sleep paralysis
• Worsening depression or suicidal ideation in depressed patients

Real-world poison center data confirms these risks, particularly with co-intoxications 4:

• Confusion, hallucinations, and coma reported with polypharmacy
• Severe outcomes occurred exclusively with co-intoxications
• Females may be at higher risk with co-intoxication (β = 1.95, P = 0.0086)

Dose-Specific Adverse Event Risk

Evidence shows dose-dependent adverse effects 5:

• 25 mg dose: Significantly increased risk of adverse events of special interest (AESIs) compared to placebo (RR 4.00,95% CI 1.64-9.76)
• 10 mg and 50 mg: Elevated risk but not statistically significant
• Somnolence frequency increases significantly at doses exceeding FDA-recommended levels

Drug Interactions Requiring Caution

CYP3A4 Interactions 1

Strong CYP3A4 inhibitors: Concomitant use NOT recommended

• Increases daridorexant exposure, raising adverse event risk

Moderate CYP3A4 inhibitors: Reduce dose to 25 mg

• Examples: diltiazem, erythromycin, fluconazole

Strong/Moderate CYP3A4 inducers: Concomitant use NOT recommended

• Reduces daridorexant efficacy

Narrow Therapeutic Index Drugs 1

Use with caution when co-administering:

• CYP3A4 substrates with narrow therapeutic index (daridorexant increases their exposure)
• P-glycoprotein substrates with narrow therapeutic index (daridorexant increases their exposure)

Special Populations

Pregnancy and Lactation 1

• Pregnancy: No human data available; animal studies show no fetal toxicity at 8-10× MRHD
• Pregnancy exposure registry available (1-833-400-9611)
• Lactation: Present in breast milk at low levels (<1% relative infant dose)
• Monitor breastfed infants for excessive sedation

Pediatric Use

Safety and effectiveness not established in pediatric patients 1

Geriatric Use 1

• No dose adjustment required for age >65 years
• However, increased vigilance necessary due to:
  • Higher likelihood of somnolence and fatigue with age
  • Substantially elevated fall risk
  • 39% of trial participants were ≥65 years; 5.9% were ≥75 years

Respiratory Safety

Daridorexant does not impair respiratory function in severe obstructive sleep apnea 6:

• No clinically meaningful effect on apnea/hypopnea index (treatment difference -3.7 events/h)
• No clinically meaningful effect on oxygen saturation (treatment difference -0.12%)
• Safe in patients with severe OSA (baseline AHI 51.2 events/h)

Overdose Experience

Real-world poison center data from 51 cases 4:

• Mono-intoxications: Generally low severity

  • Median ingested dose: 200 mg (range 100-362.5 mg)
  • Primary symptoms: somnolence, vertigo, nausea
  • No fatalities reported
  • Recovery with supportive care

• Co-intoxications: Higher severity risk

  • Particularly with benzodiazepines, antidepressants, alcohol
  • Symptoms: confusion, hallucinations, tachycardia, coma (lowest GCS = 7)
  • Females at significantly higher risk with co-intoxication

Clinical Pitfalls to Avoid

1. Do not combine with strong CYP3A4 inhibitors - increases adverse event risk substantially
2. Exercise heightened caution in elderly patients - fall risk is the primary morbidity concern
3. Screen for depression - monitor for worsening or suicidal ideation
4. Warn about next-day driving impairment - particularly within first few doses
5. Avoid alcohol completely - additive CNS depression
6. Be vigilant with polypharmacy - particularly CNS depressants and narrow therapeutic index drugs
7. Monitor breastfed infants for excessive sedation if mother taking daridorexant